The Marshall Protocol Study Site Home

Search
   
Members

Calendar

Help

Home
Search by username
   Not logged in - Login | Register 


Jensen Symposium on Nuclear Receptors
 Moderated by: Prof Trevor Marshall
 

New Topic

Reply

Print
AuthorPost
Prof Trevor Marshall
Foundation Staff


Joined: Fri Jul 9th, 2004
Location: Thousand Oaks, California USA
Posts: 15799
Status:  Offline
 Posted: Wed Oct 14th, 2009 16:58

Quote

Reply
In case you wondered why I have been busy lately, I have been preparing for the Nuclear Receptors conference in Cincinnati. I am not speaking, just mixing, learning, and asking questions..

http://www.uc.edu/conferencing/Details.asp?ConferenceID=320

About 300 were present today, a good crowd.

The last speaker of the day seemed to know quite a bit about how various ligands fitted into the Estrogen receptors, and how some even distorted its shape. When he spoke later at Dinner he was introduced as the inventor of Tamoxifen.  Duuuh... :)

I will be here another two days, if you have written me MPs or emails please be patient :X
 

Prof Trevor Marshall
Foundation Staff


Joined: Fri Jul 9th, 2004
Location: Thousand Oaks, California USA
Posts: 15799
Status:  Offline
 Posted: Thu Oct 15th, 2009 23:10

Quote

Reply
Well, this has been an amazing conference, and we still have Friday morning to go...

My over-riding impression is "complexity."  Talk about 'imponderable.' We have now learned there are not only Thyroid-alpha and beta, and Estrogen alpha and beta, but Progesterone is also alpha and beta, and the Glucocorticoid receptor has at least 5 isomers. A simple mechanism whereby a ligand can make a receptor respond more favorably to promoter regions of specific genes has been defined. Further, the Estrogen-alpha receptor has been shown to change shape to fit some of its ligands. Sigh...

It is at once great to meet researchers whom I haven't seen for months, and to catch up with what they have been doing, as it is discouraging to see that they have no overview, are still focused on mice and cell-lines, and have little clue about what human disease actually looks or feels like. They leave drug testing to their clinical colleagues. PhRMA is more interested in putting out a drug for BPH than prostate cancer, because more consumers have BPH so it is a bigger revenue stream. Sigh again...

Anyway, I will post an update when I get back home.

..Trevor..
ps: none of the leading research teams is paying any attention to the VDR... But we already knew that:X
 

Russ
inactive member
 

Joined: Fri Mar 24th, 2006
Location: Hartford, Connecticut USA
Posts: 812
Status:  Offline
 Posted: Fri Oct 16th, 2009 02:07

Quote

Reply
Thanks for the update.  Sounds like science's knowledge of what all these receptors do is expanding slowly but surely.  What aspects of the MP treatment do you think have the most potential for improvement/refinement as new knowledge comes available?



____________________
*** I recently moved to Connecticut so if anyone knows of MP docs in this state or nearby, please send me a PM. ***

 Current time is 21:10



* We can help you understand chronic disease, but only your physician is licensed to give you medical care *

Powered by WowBB 1.7 - Entire site Copyright © 2004-2020 Autoimmunity Research Foundation, All Rights Reserved
Click here to view our PRIVACY POLICY
Page processed in 0.0907 seconds (92% database + 8% PHP). 17 queries executed.